Adam Knight, Ph.D., a member of the Board of Directors of Oryon Cell Therapies. Dr. Knight is Co-Founder and Partner at Neuro.VC. He was previously Founder, Chief Executive Officer, and Chief Business Officer of Neuron23, where he raised more than $300 million from top-ranked biotech investors and advanced three programs into clinical trials (including a LRRK2 inhibitor currently in Phase 2 for Parkinson’s disease). Dr. Knight also served as a part-time Advisor for Perceptive Advisors, Evermore, and Locust Walk. Dr. Knight previously worked at Kleiner Perkins, IQVIA, and Miltenyi Biotec. He has a B.S. and M.S. from the University of Alabama and a Ph.D. from the University of Cambridge.
